Drug Profile
TAK 114
Alternative Names: Meisoindigo; Natura-α; TAK-114Latest Information Update: 23 May 2016
Price :
$50
*
At a glance
- Originator Natrogen Therapeutics International
- Developer Natrogen Therapeutics International; Takeda Pharmaceuticals International GmbH
- Class Anti-inflammatories; Indoles; Small molecules
- Mechanism of Action Cytokine modulators; Regulatory T-lymphocyte modulators; STAT3 transcription factor inhibitors; Th17 cell modulators; Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer; Systemic lupus erythematosus; Ulcerative colitis
Most Recent Events
- 10 May 2016 Discontinued - Phase-I for Ulcerative colitis in Japan (PO)
- 10 May 2016 Discontinued - Phase-II for Ulcerative colitis in European Union, USA (PO)
- 30 Nov 2014 Takeda initiates enrolment in a phase I trial in volunteers in Japan (NCT02286518)